At a glance
ClinicalIndex Comparison RecordN/ACompleted· 926 enrolled
Drug / intervention
etanercept (Enbrel®)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Non-interventional Study (Nis) Of The Routine Use Of Etanercept In The Long-term Treatment Of Patients With Plaque-type Psoriasis In Everyday Practice: An Efficacy, Safety, And Health Economic Evaluation
In Brief
An observational study evaluating etanercept (Enbrel®) for Psoriasis. Completed, enrolled 926 participants across 1 site.
Detailed Summary
This prospective observational cohort study will assess the average duration of the drug free interval between etanercept treatment cycles in usual care settings in Germany.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJul 2008
Primary CompletionDec 2013
TodayJul 2026
First PostedJul 2, 2008
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 18 years ago
Interventions
etanercept (Enbrel®)drug
The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.